| Catalog No. | DY373018 |
|---|
| Sample type | Plasma, Serum |
|---|
| Sensitivity | 40.3 ng/mL |
|---|
| Range | 78.13 - 5, 000 ng/mL |
|---|
| Accession |
P09758 |
| Applications |
ELISA |
| Detection method |
Colorimetric |
| Assay type |
Quantitative |
| Recovery |
80-120% |
| Shipping |
2-8 ℃ |
| Stability and Storage |
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃. |
| Specifications |
Sacituzumab
|
| Alternate Names | IMMU-132, hRS7-SN-38, hRS7-SN-38-ADC, hRS7-[CL-SN-38], , 1796566-95-4 |
|---|
| Background | Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received accelerated approval in the USA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Sacituzumab govitecan is undergoing phase III development for breast cancer in the USA and EU, and phase II development for urothelial cancer. It is also being explored for brain metastases, glioblastoma, endometrial cancer and prostate cancer. |
|---|
| Note |
For Research Use Only. |
